Lv4
680 积分 2023-06-12 加入
From RAS inhibitor resistance to rational combination strategies
4天前
已完结
PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
9天前
已完结
The senescence-associated secretory phenotype and its physiological and pathological implications
16天前
已完结
EGFR N-Glycosylation Catalyzed by NDST2 Promotes Lenvatinib Resistance in Hepatocellular Carcinoma
1个月前
已完结
Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors
3个月前
已完结
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer
3个月前
已完结
RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer
4个月前
已完结
The adenosine pathway in immuno-oncology
5个月前
已完结
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy
6个月前
已完结
Transarterial Chemoembolization and Immunotherapy: Another Good Marriage?
6个月前
已关闭
皖公网安备34019202002308
